
Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

